Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating Atezolizumab in Newly Diagnosed Endocrine Receptor Positive Breast Cancer Patients According to Their AdipOsity (AteBrO)

NCT04630210 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT04630210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04630210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating Atezolizumab in Newly Diagnosed Endocrine Receptor Positive Breast Cancer Patients According to Their AdipOsity (AteBrO)
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Phase 1
Overall status
Withdrawn
Start date
February 28, 2021
Completion date
January 31, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer